Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Exclusion Criteria

• •Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or is echinoderm microtubule-associated protein-like 4(EML4) gene/anaplastic lymphoma kinase (ALK) gene fusion positive
• •Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy
• •No tumor specimen evaluable for PD-L1 expression by the central study laboratory
• •Squamous histology and received carboplatin in combination with paclitaxel in the adjuvant setting
• •Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy
• •The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation
• •Expected to require any other form of systemic or localized antineoplastic therapy while on study
• •Any prior systemic cytotoxic chemotherapy, biological therapy or major surgery within 3 weeks of the first dose of study therapy; received lung radiation therapy \>30 Gy within 6 months of the first dose of study therapy
• •Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• •Known central nervous system metastases and/or carcinomatous meningitis
• •Active autoimmune disease that has required systemic treatment in the past 2 years
• •Had allogeneic tissue/solid organ transplantation
• •Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
• •Has received or will receive a live vaccine within 30 days prior to the first study therapy (seasonal flu vaccines that do not contain live vaccine are permitted)
• •Active infection requiring intravenous systemic therapy
• •Known history of human immunodeficiency virus (HIV)
• •Known active Hepatitis B or C
• •Regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)
• •Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study